Upon recruitment, patients will be placed in one of four dose-escalating cohorts.
Following completion of the dose escalation phase, the trial plan calls for a stable-dose phase in which additional patients will receive the highest safe dose.
CEQ508 will be administered daily in an oral suspension for 28 consecutive days.
Marina Biotech president and CEO Michael French said they are pleased to announce patient enrollment — a first step, in what they hope will be a rapid regulatory and clinical timeline to the commercialization of CEQ508 for the treatment of patients with FAP.
"Patients participating in the START-FAP trial will make a significant commitment throughout the trial period as each patient will undergo extensive pre- and post-dosing regimen procedures as well as daily visits by a home nurse to administer the CEQ508 dose," French said.